替诺福韦酯与替比夫定阻断乙型肝炎病毒携带孕妇病毒母婴传播的疗效和安全性比较

doi:10.3969/j.issn.1672-5069.2021.02.011

实用肝脏病杂志 ›› 2021, Vol. 24 ›› Issue (2): 192-195.doi: 10.3969/j.issn.1672-5069.2021.02.011

替诺福韦酯与替比夫定阻断乙型肝炎病毒携带孕妇病毒母婴传播的疗效和安全性比较

韩白乙拉, 索淑一, 魏冬梅, 赵志峰, 王炳元

028000 内蒙古自治区通辽市传染病医院(韩白乙拉,索淑一,魏冬梅,赵志峰);
中国医科大学附属第一医院消化内科(王炳元)

收稿日期:2020-09-10 出版日期:2021-03-10 发布日期:2021-04-30
通讯作者: 王炳元,E-mail:wangby0908@163.com
作者简介:韩白乙拉,男,57岁,大学本科,主任医师。主要从事慢性肝病的治疗和预防研究。E-mail:hanbaiyila@163.com
基金资助:
内蒙古自治区卫生与计划生育委员会科研课题(编号:201702153)

Efficacy and safety of tenofovir disoproxil fumarate and telbivudine on blocking mother-to-child transmission of hepatitis B virus infection

Hanbai Yila, Suo Shuyi, Wei Dongmei, et al

Department of Alcohol-Related Liver Diseases, Infectious Disease Hospital, Tongliao 028000,Inner Mongolia Autonomous Region, China

Received:2020-09-10 Online:2021-03-10 Published:2021-04-30

摘要/Abstract

摘要： 目的探讨妊娠中晚期应用替诺福韦酯或替比夫定阻断乙型肝炎病毒(HBV)携带孕妇母婴垂直传播的疗效和安全性。方法 2016年5月～2019年5月在通辽市传染病医院孕检的慢性HBV携带孕妇77例,在妊娠的24～28周时,按照孕妇的意愿,43例接受替诺福韦酯治疗,34例接受替比夫定治疗,在分娩后停止治疗。所有新生儿在出生后6 h内接受乙型肝炎免疫球蛋白200 IU,并在出生后0、1和6个月接种酵母源重组乙肝疫苗10μg。随访母婴至婴儿出生后7个月。结果在分娩时,两组血清HBV DNA水平均显著低于治疗前,TDF组由(7.4±1.2)lg copies/mL降低至(3.6±1.1)lg copies/mL(P＜0.05),LdT组由(7.3±1.1)lg copies/mL降低至(4.1±1.2)lg copies/mL(P＜0.05),但治疗后两组之间血清HBV DNA水平比较无显著性差异(P＞0.05);治疗前后两组血清ALT水平的变化也无显著性差异,停药后部分产妇血清ALT轻度升高,但在3个月后大部分降至正常;在出生后7个月龄时,两组新生儿血清HBsAg均为阴性,HBsAb均转为阳性;两组新生儿体质量、身高和头围比较,无显著性差异(P>0.05);两组均无明显的不良反应。结论在妊娠中晚期应用替诺福韦酯或替比夫定治疗HBV携带孕妇,可以成功阻断病毒母婴传播,结合出生后应用高效价乙肝免疫球蛋白和乙肝疫苗接种可保证婴幼儿免受HBV感染,值得进一步观察。

关键词: 乙型肝炎病毒携带者, 妊娠, 母婴传播, 替诺福韦酯, 替比夫定, 预防

Abstract: Objective The aim of this study was to investigate the efficacy and safety of tenofovir disoproxil fumarate (TDF) and telbivudine (LdT)on blocking mother-to-child transmission of hepatitis B virus infection.Methods A total of 77 pregnant women with chrnonic hepatitis B virus infection were encruited in Tongliao Infectious Disease Hospital between May 2016 and May 2019, and 43 women took TDF and 34 women took LdT from 24th to 28th weeks of gestation to cessation of pregnance. All newborns received hepatitis B immunoglobulin within 6 hours of birth and yeast-derived recombinant hepatitis B vaccine at 0, 1, and 6 months after birth. Mothers and infants were followed for 7 months after infants’ birth.Results Serum HBV DNA load in TDF-treated women decreased from(7.4±1.2)lg copies/mL to (3.6±1.1)lg copies/mL(P＜0.05), and that in LdT-treated women decreased from (7.3±1.1)lg copies/mL to (4.1±1.2)lg copies/mL(P＜0.05) before and after treatment, and there was no significant difference between the two groups; there were no significant differences respect ot serum ALT levels before and after treatment in the two groups; seven months after birth, serum HBsAg were negative and serum HBsAb were positive in all infants in the two groups and there were no significant differences respect to body mass, lengths and circumferences of head of infants in the two groups (P>0.05); we didn’t observe any side effects in the two groups during the treatment.Conclusion The administration fo TDF LdT at the base of basic hepatitis B immunoglobulin and hepatitis B vaccine inoculation might effectively block mother-to-child hepatitis B virus transmission.

Key words: Hepatitis B virus carriers, Pregnancy, Mother-to-child transmission, Tenofovir disoproxil fumarate, Telbivudine, Prevention

韩白乙拉, 索淑一, 魏冬梅, 赵志峰, 王炳元. 替诺福韦酯与替比夫定阻断乙型肝炎病毒携带孕妇病毒母婴传播的疗效和安全性比较[J]. 实用肝脏病杂志, 2021, 24(2): 192-195.

Hanbai Yila, Suo Shuyi, Wei Dongmei, et al. Efficacy and safety of tenofovir disoproxil fumarate and telbivudine on blocking mother-to-child transmission of hepatitis B virus infection[J]. Journal of Practical Hepatology, 2021, 24(2): 192-195.

参考文献

[1] 王贵强, 段钟平, 王福生, 等. 慢性乙型肝炎防治指南(2019年版). 实用肝脏病杂志, 2020, 23(1):9-32.
[2] Wu Y, Liu J, Feng Y, et al. Efficacy and safety of antiviral therapy for HBV in different trimesters of pregnancy: systematic review and network meta-analysis. Hepatol Int, 2020, 14(2):180-189.
[3] European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol, 2017, 67(2):370-398.
[4] 赵蕾, 李小丹, 刘淼. 拉米夫定与替比夫定阻断乙型肝炎病毒宫内感染的疗效和风险分析. 实用肝脏病杂志, 2020, 23(4):496-499.
[5] 范凌, 杨军, 纪风兵, 等. 妊娠中期应用替比夫定控制乙型肝炎病毒携带孕妇病毒载量及其阻断母婴传播效果分析. 实用肝脏病杂志, 2020, 23(2):179-182.
[6] Chen CL, Yang JY, Lin SF, et al. Slow decline of hepatitis B burden in general population: results from a population-based survey and longitudinal follow-up study in Taiwan. J Hepatol, 2015, 63(2):354-363.
[7] Hou J, Wang G, Wang F, et al. Guideline of prevention and treatment for chronic hepatitis B (2015 update). J Clin Transl Hepatol, 2017, 5(4):297-318.
[8] Ott JJ, Horn J, Krause G, et al. Time trends of chronic HBV infection over prior decades - a global analysis. J Hepatol, 2017, 66(1):48-54.
[9] Zhaori G. Further standardization and safety issues for antiviral therapy during pregnancy. Pediatr Investig, 2020,4(2):148-149.
[10] Hu Y, Yu H. Prevention strategies of mother-to-child transmission of hepatitis B virus (HBV) infection. Pediatr Investig, 2020, 4(2):133-137.
[11] 郭茂, 罗文强, 张大志. 以母婴阻断为目的的抗乙型肝炎病毒药物治疗的停药时间.中华肝脏病杂志, 2019, 27(2):92-96.
[12] Cheung KW, Seto MTY, Lao TT. Prevention of perinatal hepatitis B virus transmission. Arch Gynecol Obstet, 2019, 300(2):251-259.
[13] 盛秋菊, 丁洋, 李佰君, 等. HBV感染免疫耐受期孕妇应用替比夫定阻断母婴传播有效性及停药安全性的研究. 中华肝脏病杂志, 2016, 24(4):258-264.
[14] Pan CQ, Duan Z, Dai E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med, 2016, 374(24):2324-2334.
[15] Lu FT, Ni YH. Elimination of mother-to-infant transmission of hepatitis B virus: 35 years of experience. Pediatr Gastroenterol Hepatol Nutr, 2020, 23(4):311-318.
[16] Song J, Yang F, Wang S, et al. Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: a meta-analysis. J Viral Hepat, 2019, 26(3):397-406.
[17] Brown RS Jr, McMahon BJ, Lok AS, et al. Antiviral therapy in chronic hepatitis B viral infection during pregnancy: a systematic review and meta-analysis. Hepatology, 2016,63(1):319-333.
[18] Yi W, Li M, Xie Y, et al. Prospective cohort study on the efficacy and safety of telbivudine used throughout pregnancy in blocking mother‐to‐child transmission of hepatitis B virus. J Viral Hepat, 2017,24:49-56.
[19] 郭辉杰, 高云飞, 刘惠媛. 妊娠期抗病毒治疗的慢性乙型肝炎病毒感染孕妇分娩时停药对产后肝功能的影响. 中华肝脏病杂志, 2019, 27(2):112-117.
[20] Ren Y, Guo Y, Feng L, et al. Controversy and strategies exploration in blocking mother-to-child transmission of hepatitis B. Int Rev Immunol, 2016, 35:249-259.

替诺福韦酯与替比夫定阻断乙型肝炎病毒携带孕妇病毒母婴传播的疗效和安全性比较

Efficacy and safety of tenofovir disoproxil fumarate and telbivudine on blocking mother-to-child transmission of hepatitis B virus infection

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	黄永群, 黄润强, 熊平安. 替诺福韦酯联合双重免疫方案阻断HBV携带孕妇母婴病毒传播效果研究[J]. 实用肝脏病杂志, 2021, 24(3): 331-334.
[2]	王雪, 瞿发林, 戚伟利, 钱薇. 慢性乙型肝炎患者外周血Treg/Th17比值平衡及其对替比夫定治疗效果的影响[J]. 实用肝脏病杂志, 2021, 24(3): 339-342.
[3]	朱琳, 秦刚. 妊娠特有肝病诊治进展[J]. 实用肝脏病杂志, 2021, 24(3): 449-452.
[4]	贺宇峰, 钟晓妮, 黄建溶, 赖思奇. 替诺福韦酯与恩替卡韦治疗慢性乙型肝炎患者疗效和血清成纤维细胞生长因子-23水平变化[J]. 实用肝脏病杂志, 2021, 24(2): 200-203.
[5]	周娟, 刘月合, 王春佟. 应用替比夫定和替诺福韦治疗阻断血清HBV DNA高载量孕妇母婴传播的效果分析^*[J]. 实用肝脏病杂志, 2020, 23(6): 805-808.
[6]	余姣, 陈姬秀, 薛建亚, 张彩虹. 血清HBsAg阳性孕妇血清细胞因子水平对HBV母婴传播的影响[J]. 实用肝脏病杂志, 2020, 23(5): 630-633.
[7]	邢晓燕, 黄良苗, 符爱仙, 李兴钦, 韩向阳. 茵栀黄联合腺苷蛋氨酸治疗妊娠期肝内胆汁淤积症患者疗效观察及其对母婴结局的影响[J]. 实用肝脏病杂志, 2020, 23(5): 670-673.
[8]	赵蕾, 李小丹, 刘淼. 拉米夫定与替比夫定阻断乙型肝炎病毒宫内感染的疗效和风险分析^*[J]. 实用肝脏病杂志, 2020, 23(4): 496-499.
[9]	方利娟,吴雄飞. 恩替卡韦治疗乙型肝炎病毒携带者合并肺结核患者临床疗效分析[J]. 实用肝脏病杂志, 2020, 23(3): 340-343.
[10]	范凌, 杨军, 纪风兵, 周琴. 妊娠中期应用替比夫定控制乙型肝炎病毒携带孕妇病毒载量及其阻断母婴传播效果分析^*[J]. 实用肝脏病杂志, 2020, 23(2): 179-182.
[11]	丁俊琪, 张偲, 张彬. 聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎部分应答患者序贯替比夫定治疗疗效观察^*[J]. 实用肝脏病杂志, 2020, 23(1): 26-29.
[12]	周晓旭, 张华杰, 商志娟. 速度向量成像技术定量参数评估妊娠期肝内胆汁淤积症孕妇胎儿心功能研究^*[J]. 实用肝脏病杂志, 2020, 23(1): 62-65.
[13]	陈慧婷, 周永健. 妊娠期肝内胆汁淤积症诊断与管理[J]. 实用肝脏病杂志, 2020, 23(1): 153-155.
[14]	. 慢性乙型肝炎防治指南(2019年版)[J]. 实用肝脏病杂志, 2020, 23(1): 161-184.
[15]	. 丙型肝炎防治指南(2019年版)[J]. 实用肝脏病杂志, 2020, 23(1): 185-204.